NEWS
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Sonnet BioTherapeutics (NASDAQ: SONN) has announced the pricing of an underwritten public offering of 1,111,111 shares of common stock and common warrants. The offering includes common warrants to purchase up to 2,222,222 additional shares. Each share is being sold with one common warrant at a combined price of $4.50, for total gross proceeds of approximately $5.0 million. The common warrants are exercisable for five years at $4.50 per share. The offering is expected to close around November 7, 2024. The proceeds will be used for research and development, clinical trials, working capital, liability repayment, and general corporate purposes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment